Literature DB >> 26259760

Therapy-related B-lymphoblastic leukemia associated with Philadelphia chromosome and MLL rearrangement: Single institution experience and the review of the literature.

Rahul Matnani1, Vishwas Parekh1, Uma Borate2, Jason Brazelton1, Vishnu Reddy1, Deniz Peker1.   

Abstract

Therapy related acute lymphoblastic leukemia (t-ALL) of B cell origin is rare and constitutes approximately 2% of all ALL. Previously compiled data on the complete cytogenetic analysis of 48 t-B-ALL cases suggested that MLL rearrangement at 11q23 gene locus is the most common abnormality. Philadelphia chromosome (Ph) and a normal karyotype were reported as the second and third most common karyotypes, respectively. We investigated cytogenetic karyotypes of six t-B-ALL cases with a pre-B cell immunophenotype. Ph + t-B-ALL was noted in four of six patients previously treated with radiation and/or chemotherapy. In addition, one case demonstrated MLL rearrangement at 11q23 locus while one case demonstrated normal cytogenetic karyotype. Five of the six t-B-ALL patients had persistent leukemia following initiation of chemotherapy for secondary leukemia with survival ranging from 10 to 21 months. To our knowledge, only fourteen patients with Ph + t-B-ALL have been described in the literature. In the current study, three of four cases with Ph + t-B-ALL were associated with treated breast carcinoma while one patient was treated for Hodgkin lymphoma. All four patients had undergone radiation therapy. The results may indicate a plausible association between Ph+t-B-ALL and prior radiation exposure.
© 2015 Japanese Society of Pathology and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  B-ALL; MLL; Philadelphia chromosome; therapy-related

Mesh:

Substances:

Year:  2015        PMID: 26259760     DOI: 10.1111/pin.12337

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  3 in total

1.  Therapy-related acute lymphoblastic leukemia.

Authors:  Josep-Maria Ribera
Journal:  Haematologica       Date:  2018-10       Impact factor: 9.941

2.  Co-existence of IL7R high and SH2B3 low expression distinguishes a novel high-risk acute lymphoblastic leukemia with Ikaros dysfunction.

Authors:  Zheng Ge; Yan Gu; Lichan Xiao; Qi Han; Jianyong Li; Baoan Chen; James Yu; Yuka Imamura Kawasawa; Kimberly J Payne; Sinisa Dovat; Chunhua Song
Journal:  Oncotarget       Date:  2016-07-19

3.  A case of therapy-related acute lymphoblastic leukemia following the treatment of acute myeloid leukemia.

Authors:  Sufana Shikdar; Yuan Ying; Mohamad Khawandanah
Journal:  Leuk Res Rep       Date:  2022-03-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.